Aeterna Zentaris (NASDAQ:AEZS) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Aeterna Zentaris Price Performance

AEZS opened at $8.41 on Friday. The stock’s 50 day simple moving average is $8.18 and its 200 day simple moving average is $7.80. Aeterna Zentaris has a 1 year low of $5.44 and a 1 year high of $12.80. The firm has a market cap of $10.18 million, a price-to-earnings ratio of -0.57 and a beta of 1.60.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last released its earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($4.64) EPS for the quarter, missing analysts’ consensus estimates of ($3.88) by ($0.76). The firm had revenue of $0.12 million during the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications; and AEZS-150, a delayed clearance parathyroid hormonefusion polypeptide that is in preclinical trail for the treatment of hypoparathyroidism in adults.